title: [Parameters of estrogen expression in patients with endometrial tumors as prognostic signs of the effectiveness of neoadjuvant antitumor hormone therapy].
abstract: Comparison was made of changes in such morphological characteristics of tumor as cell differentiation and mitotic activity in 142 patients with endometrial carcinoma in the course of treatment, using tamoxifen or oxyprogesterone capronate or both, and those of estrogen background (karyopicnotic, eosinophilic and maturity indices, numerical index of maturity and blood-estradiol level). Three levels of estrogen background-low, medium and high-were identified by assay of the colpocytological indices in postmenopausal patients with endometrial carcinoma. Levels of the colpocytological indices observed at high indices of estrogen background proved a reliable numerical criterion for evaluating the sensitivity of the patients to neoadjuvant hormone therapy. A significant correlation was established between high estrogen background, pathogenetic variant I and high differentiation of tumor cells. The high incidence of hormonal pathology in tumor tissue was registered when the colpocytological indices dropped by half after oxyprogesterone capronate treatment, and by third-after combined therapy (tamoxifen + oxyprogesterone capronate). In cases free from pronounced pathomorphism, said indices dropped by not more than 20%.
authors.forename: N A
authors.initials: NA
authors.lastname: Ermakova
authors.forename: I V
authors.initials: IV
authors.lastname: Bokhman
authors.forename: A S
authors.initials: AS
authors.lastname: Vishnevskiĭ
authors.forename: O F
authors.initials: OF
authors.lastname: Chepik
authors.forename: S I
authors.initials: SI
authors.lastname: Maksimov
authors.forename: E V
authors.initials: EV
authors.lastname: Tsyrlina
authors.forename: N A
authors.initials: NA
authors.lastname: Mikaia
authors.forename: E L
authors.initials: EL
authors.lastname: Nezhentseva
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology; D004965:Estrogen Antagonists / Q000008:administration & dosage; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage; D008875:Middle Aged; D017698:Postmenopause; D011379:Prognosis; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D006908:Hydroxyprogesterones; D013629:Tamoxifen; D000077713:17 alpha-Hydroxyprogesterone Caproate
vernacular_title: Pokazateli vyrazhennosti èstrogennogo fona u bol'nykh rakom èndometriia kak prognosticheskiĭ kriteriĭ protivoopukholevoĭ èffektivnosti neoad''iuvantnoĭ gormonoterapii.